DVL3 and cervical cancer: Upon treatment of metformin, several cervical cancer cell lines displayed differential responses to metformin and showed depletion of DVL3 in a dose-dependent manner (Figure 3E), along with no change in the mRNA level of DVL3 in C33A and HeLa (Figure 4A), suggesting that the reduction of DVL3 regulated by AMPK activators was associated with post-transcriptional events.